18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: Diagnostic comparison and survival analysis

Journal of Nuclear Medicine

Volumn 52, Issue 4, 2011, Pages 519-525

  Nikolaos D Papathanasiou, ^a   Gaze, Mark N ^a   Sullivan, Kevin ^a   Aldridge, Matthew ^a   Waddington, Wendy ^a   Almuhaideb, Ahmad ^a   Bomanji, Jamshed B ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

123I metaiodobenzylguanidine (123I MIBG); 18F fluorodeoxyglucose (18F FDG); Neuroblastoma; Positron emission tomography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; FLUORODEOXYGLUCOSE F 18; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; TOPOTECAN; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW DISEASE; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; NEUROBLASTOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION EXPOSURE; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; BONE MARROW CANCER; COMPARATIVE STUDY; IMAGE PROCESSING; KAPLAN MEIER METHOD; LIVER TUMOR; METASTASIS; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SURVIVAL; TUMOR RECURRENCE;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADULT; BONE MARROW NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; YOUNG ADULT;

EID: 79954603164     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083303     Document Type: Article

References (25)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106-2120. (Pubitemid 46935947)
2. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173. (Pubitemid 29480654)
3. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol. 2008;9: 247-256. (Pubitemid 351722944)
4. Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51:747-753.
5. Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2007;37:286-302. (Pubitemid 46828965)
6. Kushner BH. Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med. 2004;45:1172-1188. (Pubitemid 47611663)
7. Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol. 2009;27:1041-1046.
8. Vik TA, Pfluger T, Kadota R, et al. 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784-790.
9. Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma 1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97. Eur J Cancer. 2008;44:1552-1558.
10. Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007;37:316-331. (Pubitemid 47247399)
11. Kleis M, Daldrup-Link H, Matthay K, et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging.2009;36:23-36.
12. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: Fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol. 2001;19:3397-3405. (Pubitemid 32642193)
13. 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237-1243.
14. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy- D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology.1996;199:743-750.
15. 18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27:5343-5349.
16. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm.2005;20:195-199. (Pubitemid 40696102)
17. Katzenstein HM, Cohn SL, Shore RM, et al. Scintigraphic response by 123Imetaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol. 2004;22:3909-3915. (Pubitemid 41079872)
18. Messina JA, Cheng SC, Franc BL, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006;47:865-874. (Pubitemid 44656106)
19. Colavolpe C, Guedj E, Cammilleri S, Taieb D, Mundler O, Coze C. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2008;51:828-831.
20. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen. Nucl Med Commun. 1998;19:641-647. (Pubitemid 28368315)
21. 18F-FDG. Cancer. 2008;112:2447-2455.
22. 18F]FLT-PET. Anticancer Res. 2006;26(5A):3467-3472. (Pubitemid 44701524)
23. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008;35(suppl 1):S35-S48.
24. Brans B, Laureys G, Schelfhout V, et al. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: Lack of relation to tumour differentiation in vivo. Eur J Nucl Med. 1998;25:144-149. (Pubitemid 28130038)
25. Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem. 2009;107:46-57.